➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Colorcon
Medtronic
Harvard Business School
McKinsey

Last Updated: February 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLONIDINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Clonidine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000800 Methadone Effects on Zidovudine (ZDV, AZT) Disposition Completed Glaxo Wellcome Phase 1 1969-12-31 To determine whether methadone maintenance alters the pharmacokinetics of zidovudine (AZT). To determine whether any such effect of methadone on disposition of AZT is time dependent and whether a metabolic interaction between AZT and methadone exists. Injection drug users represent an increasing proportion of HIV-infected persons. Since daily methadone maintenance is the major chemical treatment for injection drug abuse, it is important to determine the impact of methadone on AZT absorption, distribution, and elimination.
NCT00000800 Methadone Effects on Zidovudine (ZDV, AZT) Disposition Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 1969-12-31 To determine whether methadone maintenance alters the pharmacokinetics of zidovudine (AZT). To determine whether any such effect of methadone on disposition of AZT is time dependent and whether a metabolic interaction between AZT and methadone exists. Injection drug users represent an increasing proportion of HIV-infected persons. Since daily methadone maintenance is the major chemical treatment for injection drug abuse, it is important to determine the impact of methadone on AZT absorption, distribution, and elimination.
NCT00003771 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1997-09-01 RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It is not yet known if hormone replacement therapy increases the risk of breast cancer recurrence in women previously treated for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the risk of breast cancer recurrence in women with previous early stage breast cancer who are receiving hormone replacement therapy for menopause symptoms.
NCT00003771 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed International Breast Cancer Study Group Phase 3 1997-09-01 RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It is not yet known if hormone replacement therapy increases the risk of breast cancer recurrence in women previously treated for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the risk of breast cancer recurrence in women with previous early stage breast cancer who are receiving hormone replacement therapy for menopause symptoms.
NCT00003771 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed Scandinavian Breast Group Phase 3 1997-09-01 RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It is not yet known if hormone replacement therapy increases the risk of breast cancer recurrence in women previously treated for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the risk of breast cancer recurrence in women with previous early stage breast cancer who are receiving hormone replacement therapy for menopause symptoms.
NCT00003771 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed Regional Oncologic Center Phase 3 1997-09-01 RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It is not yet known if hormone replacement therapy increases the risk of breast cancer recurrence in women previously treated for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the risk of breast cancer recurrence in women with previous early stage breast cancer who are receiving hormone replacement therapy for menopause symptoms.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clonidine

Condition Name

Condition Name for Clonidine
Intervention Trials
Postoperative Pain 16
Pain 14
Hypertension 12
Pain, Postoperative 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Clonidine
Intervention Trials
Pain, Postoperative 33
Syndrome 13
Hypertension 12
Delirium 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Clonidine

Trials by Country

Trials by Country for Clonidine
Location Trials
United States 221
Egypt 28
France 16
Brazil 14
Canada 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Clonidine
Location Trials
New York 18
Maryland 16
Texas 14
California 14
Ohio 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Clonidine

Clinical Trial Phase

Clinical Trial Phase for Clonidine
Clinical Trial Phase Trials
Phase 4 85
Phase 3 42
Phase 2/Phase 3 10
[disabled in preview] 84
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Clonidine
Clinical Trial Phase Trials
Completed 122
Recruiting 62
Not yet recruiting 52
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Clonidine

Sponsor Name

Sponsor Name for Clonidine
Sponsor Trials
National Institute on Drug Abuse (NIDA) 12
Assiut University 12
Cairo University 9
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Clonidine
Sponsor Trials
Other 369
NIH 28
Industry 27
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
Dow
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.